Private Sector Global Health R&D Project

University of New England biomedical research lab manager Brittany Roy works in Ian Meng's laboratory in Biddeford

Assessing the challenges, opportunities, and investment options in global health R&D

Tuesday, April 24, 2018

Ruth Munyao, a pharmacist, dispenses anti-retroviral (ARV) drugs at the Mater Hospital in Kenya's capital Nairobi, September 10, 2015. Most of the 3,000 patients at Mater Hospital's Comprehensive Care Clinic, dedicated to HIV/AIDS treatment, come from nearby shanty towns. In Kenya, HIV prevalence among adults has almost halved since the mid-1990s to 5.3 percent in 2014, according to UNAIDS. Yet HIV/AIDS remains the leading cause of death in Kenya, responsible for nearly three in 10 deaths in the east African country, where 1.6 million Kenyans are infected, government data in 2014 shows. Picture taken September 10, 2015. To match Special Series DEVELOPMENT-GOALS/KENYA-HEALTH REUTERS/Thomas Mukoya - GF10000201330

How profitable are HIV drugs?

Jake Schneider and Darrell M. West

Monday, April 16, 2018

Less than four percent of private investment in health R&D targets the developing world

Friday, April 6, 2018

Technician Matthew Smith loads a robotic DNA sample automation machine

Five ways to improve private investment in global health R&D

Jake Schneider and Darrell M. West

Wednesday, March 28, 2018

A pharmacy employee looks for medication.

Are drugs for neglected diseases profitable?

Jake Schneider and Jeremy Barofsky

Tuesday, December 19, 2017

Michael Otieno, a pharmacist, dispenses anti-retroviral (ARV) drugs at the Mater Hospital in Kenya's capital Nairobi, September 10, 2015. Most of the 3,000 patients at Mater Hospital's Comprehensive Care Clinic, dedicated to HIV/AIDS treatment, come from nearby shanty towns. In Kenya, HIV prevalence among adults has almost halved since the mid-1990s to 5.3 percent in 2014, according to UNAIDS. Yet HIV/AIDS remains the leading cause of death in Kenya, responsible for nearly three in 10 deaths in the east African country, where 1.6 million Kenyans are infected, government data in 2014 shows. Picture taken September 10, 2015. To match Special Series DEVELOPMENT-GOALS/KENYA-HEALTH REUTERS/Thomas Mukoya - GF10000201331

Factors limiting private sector investment in global health R&D

Darrell M. West

Monday, December 4, 2017

lab research

How much does the private sector invest in global health R&D?

Jake Schneider, John Villasenor, and Darrell M. West

Tuesday, September 12, 2017

Cholera patients receive treatment and care inside a special ward at the Kenyatta National Hospital in Nairobi, Kenya July 19, 2017. REUTERS/Thomas Mukoya - RTX3C2A7

How the Trump budget harms global health and weakens international stability

Jake Schneider and Darrell M. West

Thursday, July 27, 2017

pharmaceutical lab

Forum on health governance capacity sees bigger role for private R&D investment

Darrell M. West, John Villasenor, and Jake Schneider

Friday, April 14, 2017

Research scientist Dan Galperin works in the research labaratory at Protein Sciences Inc. where they are working on developing a vaccine for the Zika virus

Brookings report assesses health governance capacity in low- and middle-income countries

Jake Schneider, John Villasenor, and Darrell M. West

Wednesday, March 29, 2017